Custom-made cancer vaccine reduces the risk of the disease returning - critical summary review

Most vaccines are made in advance and in bulk, against something that has not happened to you yet — a virus you might catch. What Merck and Moderna have been testing is close to the opposite: it is manufactured for one person, after that person has already had cancer surgery, from the genetic signature of the tumor that was removed. There is no batch of it waiting in a fridge. Each dose exists because one specific tumor existed.

The idea has circulated in oncology for years as an ambition. It has now produced its first positive result in a large, late-stage trial: in patients operated on for high-risk melanoma, a form of skin cancer, the personalized shot added to standard treatment significantly reduced the risk that the disease would come back or spread, the two companies announced.

What a personalized cancer vaccine actually does

The technical name of the product is intismeran autogene, and the word "vaccine" here works differently from the everyday sense. It is a therapeutic vaccine, given after surgery, and its job is not to keep a healthy person from getting sick — it is to train the immune system to hunt down cancer cells that surgery may have left behind.

The manufacturing sequence explains the "personalized" part. After the tumor is removed, doctors sample both the cancerous tissue and healthy cells. Algorithms then read the tumor's genetic sequence and pick up to 34 neoantigens — markers specific to that tumor and absent from normal tissue — which are encoded in mRNA and turned into the individual treatment.

Why go to that trouble? Because tumors are not interchangeable. "They're slightly different in every patient, which is why traditional chemotherapies often stop working or don't work in a particular patient," said Dr. Murad Alam, vice chair of dermatology at Northwestern Medicine in Chicago, speaking to Fox News Digital. "This is almost individualized immunotherapy, where you're finding specific issues in a particular patient." The point of aiming at tumor-specific targets, he said, is that "it doesn't hit normal cells, and it hits the cancer cells very effectively because it's not just a generic vaccine."

It is also worth being clear about who this is not for. According to Alam, it is not meant to prevent melanoma in people who do not have it, even those with a family history, and it is not meant for very small melanomas. "This is designed for people where the melanoma has grown to the point where it's threatening not just the local area of the skin, but their whole lives," he said.

The trial that moved the idea out of the "aspirational" column

The study is called INTerpath-001 and enrolled 1,137 patients worldwide, all of whom had undergone surgery to remove high-risk melanoma — classified as Stage IIB through Stage IV. They were randomly assigned to one of two arms: Keytruda, Merck's standard-of-care immunotherapy in this setting, plus the personalized vaccine; or Keytruda plus a placebo.

Patients in the combination arm did significantly better on recurrence-free survival, meaning their cancer was less likely to return. The combination also significantly improved distant metastasis-free survival, a measure of how long patients stayed alive without the cancer spreading to distant parts of the body.

According to the companies, this is the first positive Phase 3 trial of an mRNA-based personalized cancer therapy — the reason the announcement registered well beyond melanoma specialists. "These Phase 3 findings represent a pivotal moment for the field of cancer research," Moderna chief executive Stéphane Bancel said in the companies' release. "For many years, the idea of creating an mRNA treatment designed specifically for an individual patient's cancer was aspirational. We are now helping turn that vision into a reality."

Merck said side effects were similar to those seen in earlier studies, with no new safety concerns identified. Alam described the tolerability as unusual for cancer care: "When you're getting very strong cancer medications, even when they work, the toll on the patient is often terrible." With this approach, he said, "the side effects are really mild — a little fatigue, a little chills, some injection side pain."

Why artificial intelligence sits in the middle of this

The bottleneck in a made-to-order treatment is not the idea, it is the time. Somebody has to decide, for each patient, which handful of mutations out of an entire tumor genome are worth putting into the shot — and the answer is different every time.

That is the step Alam credits to computation. "These things are difficult, and, historically, [they] took a lot of time, and it just wouldn't be feasible to do this for every individual patient without the power of AI," he said. "And I'm sure that will become better and better in the future." What the tooling buys, in his description, is practicality: "Here, AI is a tool that allows you in a reasonable amount of time, with a reasonable amount of resources... to come up with a vaccine for that individual person."

What the announcement did not show

The result is significant on the measures the trial was built around, but several things it does not answer are worth naming, because they are the ones that decide how big this turns out to be.

The announcement did not reveal how long patients actually remained cancer-free. It also did not establish whether the treatment helps patients live longer — overall survival is simply not what these results speak to. The recurrence-free survival findings, the release noted, were based on investigator assessments rather than an independent central review.

And the population was narrow by design: people with specific stages of skin melanoma who had surgery and had received no prior drug treatment. The findings may not carry over to other types or stages of cancer.

Approval, and then lung, bladder and kidney

Two things follow from here. The first is regulatory. Merck and Moderna have said they plan to engage with regulatory authorities worldwide, including the US Food and Drug Administration, about potential filings for the treatment — that is the announced intention, and the concrete milestone to watch is whether a filing is actually submitted.

The second is scope. The companies have plans in the works to test the technology against other hard-to-treat cancers, including lung, bladder and kidney. Alam thinks the logic travels: "The underlying concept of targeting a particular tumor with the specific markers on that tumor is generalizable, meaning you could do this with different kinds of skin cancer or different kinds of cancer in general."

What is known — and what is still unknown

Known: in a trial of more than a thousand patients operated on for high-risk melanoma, adding a vaccine built from each patient's own tumor to standard immunotherapy significantly reduced the risk of the cancer returning and of it spreading to distant parts of the body. The treatment is given after surgery, not as prevention. Its targets — up to 34 per patient — are selected computationally from the tumor's genetic sequence. Side effects matched what earlier studies had shown, with no new safety concerns flagged. And the companies say this is the first late-stage trial in which an mRNA personalized cancer therapy has worked.

Unknown: how long the patients stayed free of disease, and whether any of this translates into longer lives — neither question is answered by what was announced. Whether the recurrence benefit holds up under an independent central review, rather than investigator assessment, is also open. So is everything outside the trial's narrow entry criteria: other stages, other cancers, patients who had prior drug treatment.

What to follow, then, is not more discussion of the melanoma numbers. It is whether a regulatory filing actually lands, and what the trials in lung, bladder and kidney show — because that is where it becomes clear whether a vaccine designed one patient at a time is a melanoma result or a way of treating cancer.